ACRP CCRA TEST 2025/2026 BANK 2 VERSIONS
CURRENTLY TESTING COMPLETE EXAM
QUESTIONS WITH DETAILED VERIFIED ANSWERS
EXPERT VERIFIED /ALREADY GRADED A+.
1. What is the primary purpose of the ICH GCP E6 guideline?
...ANSWER... To provide a unified standard for the European Union, Japan, and the United
States to facilitate the mutual acceptance of clinical data by regulatory authorities.
2. According to ICH GCP, what is the essential document that describes the objective(s), design,
methodology, statistical considerations, and organization of a trial?
...ANSWER... The Protocol.
3. Define an Adverse Drug Reaction (ADR) as per ICH GCP.
...ANSWER... All noxious and unintended responses to a medicinal product related to any dose.
The term "medicinal product" implies a causal relationship.
4. What is the key difference between an Adverse Event (AE) and a Serious Adverse Event
(SAE)?
...ANSWER... An AE is any untoward medical occurrence in a patient administered a
pharmaceutical product, which does not necessarily have a causal relationship with the treatment.
An SAE is any AE that results in death, is life-threatening, requires inpatient hospitalization or
prolongation of existing hospitalization, results in persistent or significant disability/incapacity,
or is a congenital anomaly/birth defect.
5. List the four types of SAEs that require prompt reporting to the sponsor, even if the event is
listed in the Investigator's Brochure as expected.
...ANSWER... Fatal or life-threatening SAEs.
6. What is the primary responsibility of a Clinical Research Associate (CRA)?
...ANSWER... To monitor the conduct of the clinical trial at the investigative site to ensure
compliance with the protocol, GCP, and applicable regulatory requirements.
7. What is Informed Consent?
,...ANSWER... A process by which a subject voluntarily confirms his or her willingness to
participate in a particular trial, after having been informed of all aspects of the trial that are
relevant to the subject's decision to participate.
8. Name the three fundamental ethical principles outlined in the Belmont Report.
...ANSWER... Respect for Persons, Beneficence, and Justice.
9. What is the purpose of a Monitoring Visit Report (MVR)?
...ANSWER... To document the findings, deviations, and action items from a site monitoring
visit and to provide a formal communication to the site and the sponsor.
10. What is the difference between a protocol deviation and a protocol violation?
...ANSWER... A deviation is a minor, unintentional departure from the protocol that does not
significantly impact the subject's rights, safety, or welfare, or the integrity of the data. A violation
is a more significant, intentional or unintentional departure that can impact data integrity or
subject safety.
11. What document must be reviewed and updated whenever new safety information becomes
available that is relevant to the trial?
...ANSWER... The Investigator's Brochure (IB).
12. What is the role of an Independent Ethics Committee (IEC) or Institutional Review Board
(IRB)?
...ANSWER... To safeguard the rights, safety, and well-being of all trial subjects by providing
independent review and approval of the trial protocol, informed consent form, and other relevant
documents.
13. When must a subject's informed consent be obtained?
...ANSWER... Before any protocol-specific procedures are performed or any trial-related data is
collected.
14. What is source data verification (SDV)?
...ANSWER... The process by which data transcribed from the source documents to the Case
Report Form (CRF) are checked for accuracy, completeness, and veracity.
,15. Define "blinding" in a clinical trial.
...ANSWER... A procedure in which one or more parties to the trial are kept unaware of the
treatment assignment(s).
16. What is a Clinical Study Report (CSR)?
...ANSWER... A final comprehensive report that describes the methodology and results of a
clinical trial, forming the basis for submissions to regulatory authorities.
17. What is the purpose of a site initiation visit (SIV)?
...ANSWER... To ensure the site is fully prepared to begin enrolling subjects, which includes
training the site staff on the protocol, GCP, data entry, and study-specific procedures.
18. What is the essential document that provides a summary of the clinical trial conduct and
results, intended for submission to regulatory authorities?
...ANSWER... The Clinical Study Report (CSR).
19. What does ALCOA+ stand for in the context of data integrity?
...ANSWER... Attributable, Legible, Contemporaneous, Original, Accurate, plus Complete,
Consistent, Enduring, and Available.
20. Who is responsible for the accuracy and completeness of the data reported in the Case Report
Form (CRF)?
...ANSWER... The Principal Investigator.
21. What is a Coordinating Investigator?
...ANSWER... An investigator assigned the responsibility for the coordination of investigators at
different centers in a multi-center trial.
22. What is the definition of a Non-Serious Adverse Event?
...ANSWER... Any adverse event that does not meet the criteria for a serious adverse event.
, 23. What is the primary goal of a pre-study qualification visit (also known as a site selection
visit)?
...ANSWER... To assess the suitability of the potential investigative site and its staff for
participation in the clinical trial.
24. What is a Direct Access Clause in a clinical trial agreement?
...ANSWER... A clause that grants regulatory authorities and sponsors the right to access a
subject's original medical records for verification of data.
25. What is the purpose of a Trial Master File (TMF)?
...ANSWER... To demonstrate that the clinical trial has been conducted in compliance with the
protocol, GCP, and applicable regulatory requirements.
26. What is a Suspected Unexpected Serious Adverse Reaction (SUSAR)?
...ANSWER... A serious adverse event that is both unexpected (not consistent with the reference
safety information in the IB) and suspected to be related to the investigational product.
27. Who is responsible for obtaining informed consent from a potential research subject?
...ANSWER... The Principal Investigator or a qualified, delegated sub-investigator.
28. What is the key difference between an amendment and an errata in the context of a protocol?
...ANSWER... An amendment is a formal change to the protocol that requires IRB/IEC approval
before implementation. An errata is a correction of a typographical or administrative error that
does not affect the scientific intent or subject safety and may not always require re-approval.
29. What is the purpose of a close-out visit?
...ANSWER... To ensure that all trial-related activities are complete, all data queries are resolved,
the investigational product is accounted for, and essential documents are archived appropriately.
30. Define "vulnerable population" in clinical research.
...ANSWER... A group of individuals whose capacity to give voluntary, informed consent is
compromised due to coercion, undue influence, or diminished autonomy.
CURRENTLY TESTING COMPLETE EXAM
QUESTIONS WITH DETAILED VERIFIED ANSWERS
EXPERT VERIFIED /ALREADY GRADED A+.
1. What is the primary purpose of the ICH GCP E6 guideline?
...ANSWER... To provide a unified standard for the European Union, Japan, and the United
States to facilitate the mutual acceptance of clinical data by regulatory authorities.
2. According to ICH GCP, what is the essential document that describes the objective(s), design,
methodology, statistical considerations, and organization of a trial?
...ANSWER... The Protocol.
3. Define an Adverse Drug Reaction (ADR) as per ICH GCP.
...ANSWER... All noxious and unintended responses to a medicinal product related to any dose.
The term "medicinal product" implies a causal relationship.
4. What is the key difference between an Adverse Event (AE) and a Serious Adverse Event
(SAE)?
...ANSWER... An AE is any untoward medical occurrence in a patient administered a
pharmaceutical product, which does not necessarily have a causal relationship with the treatment.
An SAE is any AE that results in death, is life-threatening, requires inpatient hospitalization or
prolongation of existing hospitalization, results in persistent or significant disability/incapacity,
or is a congenital anomaly/birth defect.
5. List the four types of SAEs that require prompt reporting to the sponsor, even if the event is
listed in the Investigator's Brochure as expected.
...ANSWER... Fatal or life-threatening SAEs.
6. What is the primary responsibility of a Clinical Research Associate (CRA)?
...ANSWER... To monitor the conduct of the clinical trial at the investigative site to ensure
compliance with the protocol, GCP, and applicable regulatory requirements.
7. What is Informed Consent?
,...ANSWER... A process by which a subject voluntarily confirms his or her willingness to
participate in a particular trial, after having been informed of all aspects of the trial that are
relevant to the subject's decision to participate.
8. Name the three fundamental ethical principles outlined in the Belmont Report.
...ANSWER... Respect for Persons, Beneficence, and Justice.
9. What is the purpose of a Monitoring Visit Report (MVR)?
...ANSWER... To document the findings, deviations, and action items from a site monitoring
visit and to provide a formal communication to the site and the sponsor.
10. What is the difference between a protocol deviation and a protocol violation?
...ANSWER... A deviation is a minor, unintentional departure from the protocol that does not
significantly impact the subject's rights, safety, or welfare, or the integrity of the data. A violation
is a more significant, intentional or unintentional departure that can impact data integrity or
subject safety.
11. What document must be reviewed and updated whenever new safety information becomes
available that is relevant to the trial?
...ANSWER... The Investigator's Brochure (IB).
12. What is the role of an Independent Ethics Committee (IEC) or Institutional Review Board
(IRB)?
...ANSWER... To safeguard the rights, safety, and well-being of all trial subjects by providing
independent review and approval of the trial protocol, informed consent form, and other relevant
documents.
13. When must a subject's informed consent be obtained?
...ANSWER... Before any protocol-specific procedures are performed or any trial-related data is
collected.
14. What is source data verification (SDV)?
...ANSWER... The process by which data transcribed from the source documents to the Case
Report Form (CRF) are checked for accuracy, completeness, and veracity.
,15. Define "blinding" in a clinical trial.
...ANSWER... A procedure in which one or more parties to the trial are kept unaware of the
treatment assignment(s).
16. What is a Clinical Study Report (CSR)?
...ANSWER... A final comprehensive report that describes the methodology and results of a
clinical trial, forming the basis for submissions to regulatory authorities.
17. What is the purpose of a site initiation visit (SIV)?
...ANSWER... To ensure the site is fully prepared to begin enrolling subjects, which includes
training the site staff on the protocol, GCP, data entry, and study-specific procedures.
18. What is the essential document that provides a summary of the clinical trial conduct and
results, intended for submission to regulatory authorities?
...ANSWER... The Clinical Study Report (CSR).
19. What does ALCOA+ stand for in the context of data integrity?
...ANSWER... Attributable, Legible, Contemporaneous, Original, Accurate, plus Complete,
Consistent, Enduring, and Available.
20. Who is responsible for the accuracy and completeness of the data reported in the Case Report
Form (CRF)?
...ANSWER... The Principal Investigator.
21. What is a Coordinating Investigator?
...ANSWER... An investigator assigned the responsibility for the coordination of investigators at
different centers in a multi-center trial.
22. What is the definition of a Non-Serious Adverse Event?
...ANSWER... Any adverse event that does not meet the criteria for a serious adverse event.
, 23. What is the primary goal of a pre-study qualification visit (also known as a site selection
visit)?
...ANSWER... To assess the suitability of the potential investigative site and its staff for
participation in the clinical trial.
24. What is a Direct Access Clause in a clinical trial agreement?
...ANSWER... A clause that grants regulatory authorities and sponsors the right to access a
subject's original medical records for verification of data.
25. What is the purpose of a Trial Master File (TMF)?
...ANSWER... To demonstrate that the clinical trial has been conducted in compliance with the
protocol, GCP, and applicable regulatory requirements.
26. What is a Suspected Unexpected Serious Adverse Reaction (SUSAR)?
...ANSWER... A serious adverse event that is both unexpected (not consistent with the reference
safety information in the IB) and suspected to be related to the investigational product.
27. Who is responsible for obtaining informed consent from a potential research subject?
...ANSWER... The Principal Investigator or a qualified, delegated sub-investigator.
28. What is the key difference between an amendment and an errata in the context of a protocol?
...ANSWER... An amendment is a formal change to the protocol that requires IRB/IEC approval
before implementation. An errata is a correction of a typographical or administrative error that
does not affect the scientific intent or subject safety and may not always require re-approval.
29. What is the purpose of a close-out visit?
...ANSWER... To ensure that all trial-related activities are complete, all data queries are resolved,
the investigational product is accounted for, and essential documents are archived appropriately.
30. Define "vulnerable population" in clinical research.
...ANSWER... A group of individuals whose capacity to give voluntary, informed consent is
compromised due to coercion, undue influence, or diminished autonomy.
